These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 21042281)

  • 41. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
    Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
    Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
    Falchi M; Varricchio L; Martelli F; Marra M; Picconi O; Tafuri A; Girelli G; Uversky VN; Migliaccio AR
    Exp Hematol; 2017 Jun; 50():53-76. PubMed ID: 28232234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E
    Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms.
    Fung TK; Cheung AM; Kwong YL; Liang R; Leung AY
    Leuk Res; 2010 Oct; 34(10):1390-4. PubMed ID: 20170959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
    Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
    Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice.
    Jin X; Zhao W; Kirabo A; Park SO; Ho WT; Sayeski PP; Zhao ZJ
    J Immunol; 2014 Jul; 193(2):477-84. PubMed ID: 24920845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic effects of hepatocyte growth factor on human cord blood CD34+ progenitor cells are the result of c-met receptor expression.
    Goff JP; Shields DS; Petersen BE; Zajac VF; Michalopoulos GK; Greenberger JS
    Stem Cells; 1996 Sep; 14(5):592-602. PubMed ID: 8888500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
    James C; Ugo V; Le Couédic JP; Staerk J; Delhommeau F; Lacout C; Garçon L; Raslova H; Berger R; Bennaceur-Griscelli A; Villeval JL; Constantinescu SN; Casadevall N; Vainchenker W
    Nature; 2005 Apr; 434(7037):1144-8. PubMed ID: 15793561
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells.
    Zeuner A; Pedini F; Signore M; Ruscio G; Messina C; Tafuri A; Girelli G; Peschle C; De Maria R
    Blood; 2006 May; 107(9):3495-502. PubMed ID: 16384930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
    Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
    Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+).
    Weimar IS; Miranda N; Muller EJ; Hekman A; Kerst JM; de Gast GC; Gerritsen WR
    Exp Hematol; 1998 Aug; 26(9):885-94. PubMed ID: 9694510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
    Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.
    Steimle C; Lehmann U; Temerinac S; Goerttler PS; Kreipe H; Meinhardt G; Heimpel H; Pahl HL
    Ann Hematol; 2007 Apr; 86(4):239-44. PubMed ID: 17256145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
    Gaikwad A; Prchal JT
    Exp Hematol; 2007 Nov; 35(11):1647-56. PubMed ID: 17976517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
    Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; Thanigaikumar M; Yallop D; Arya R; Pagliuca A; Gäken J; Wendon J; Heaton ND; Mufti GJ
    Gastroenterology; 2006 Jun; 130(7):2031-8. PubMed ID: 16762626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.
    Li J; Kent DG; Godfrey AL; Manning H; Nangalia J; Aziz A; Chen E; Saeb-Parsy K; Fink J; Sneade R; Hamilton TL; Pask DC; Silber Y; Zhao X; Ghevaert C; Liu P; Green AR
    Blood; 2014 May; 123(20):3139-51. PubMed ID: 24692758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Altered Ca
    Buks R; Dagher T; Rotordam MG; Monedero Alonso D; Cochet S; Gautier EF; Chafey P; Cassinat B; Kiladjian JJ; Becker N; Plo I; Egée S; El Nemer W
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.